ArticleVeterinary research communications2025
Central administration of C-type natriuretic peptide (CNP) modulates food consumption in broilers: involvement of dopaminergic, melanocortinergic, and neuropeptide Y receptors.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-type natriuretic peptide (CNP), belonging to the natriuretic peptide group, has recently emerged as a potential modulator of feeding behavior in mammalian species. This study aimed to examine the impact of central infusion of CNP-22 on feeding behavior in neonatal broilers and to elucidate its interaction with the dopaminergic, malanocortinergic, and neuropeptide Y (NPY) systems. Across ten separate experiments, broilers were systematically allocated into four different treatment groups for each experiment. In the initial experiment, neonatal chickens (Ross-308) received ICV injections of saline or CNP-22 at escalating doses (0.75, 1.5, and 3 nmol). Subsequent experiments assessed the interplay between CNP-22 (3 nmol); L-DOPA, a precursor of dopamine; 6-hydroxydopamine (6-OHDA), a neurotoxin targeting dopaminergic neurons; SCH23390, an antagonist of D1 dopamine receptors; AMI-193, an antagonist of D2 dopamine receptors; SHU9119, an antagonist of melanocortin 3 and 4 receptors; HS 024, a selective melanocortin 4 receptor antagonist; BMS193885, an antagonist of the neuropeptide Y1 receptor; CYM9484, an antagonist of the neuropeptide Y2 receptor; and L-152,804, which functions as an antagonist at neuropeptide Y5 receptors. Treatments included individual injections and simultaneous co-administrations of CNP-22 with these pharmacological agents. Feed consumption was measured for 120 min post-infusion. When CNP-22 was administered at concentrations of 1.5 and 3 nmol, a progressive decline in meal consumption was observed, correlating with increasing dosage (P < 0.05). Co-infusion of BMS193885 + CNP-22 enhanced the anorexigenic effect induced by CNP-22 (P < 0.05). However, simultaneous infusion of 6-OHDA, SCH23390, and SHU9119 with CNP-22 markedly decreased CNP-22-induced anorexia (P < 0.05). The data indicate that CNP-22 administration suppresses feeding behavior in young broiler chickens, a process potentially mediated via the D1, MC3/MC4, and NPY1 receptors pathways.
Indexed as
Identifiers
41182587What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.